·] Ordinary Shares Par Value NIS 0.01 MEDIWOUND LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products • New York
FORM OF INDEMNIFICATION AGREEMENTForm of Indemnification Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of , 20 , is entered into by and between MediWound Ltd., an Israeli company whose address is 42 Hayarkon Street, Yavne 81227 , Israel (the “Company”), and , the/a [insert position of the officer] of the Company whose address is (the “Indemnitee”).
MediWound Ltd. Yavne IsraelMediWound Ltd. • March 3rd, 2014 • Medicinal chemicals & botanical products
This letter confirms our agreement and undertaking that subject to and following the initial public offering of the ordinary shares of MediWound Ltd. (the “Company”) on the Nasdaq Global Market, provided that such offering is consummated not later than August 31, 2014, Clal Biotechnology Industries Ltd. (the “Shareholder”) shall be entitled to the information rights set forth in this letter agreement (this “Agreement”), subject to the terms set forth herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of this day of March 2014, by and among (i) MediWound Ltd., an Israeli company (the “Company”), and (ii) each holder of the Company’s Ordinary Shares, nominal value NIS 0.01 each (“Ordinary Shares”) listed on Schedule A hereto (the “Shareholders”).
February 18, 2014 Letter Agreement Re: Post-Repurchase TermsWaiver and Termination Agreement • March 3rd, 2014 • MediWound Ltd. • Medicinal chemicals & botanical products
This shall serve to confirm the agreements between Teva Pharmaceutical Industries Ltd. (“Teva”) and MediWound Ltd. (“MediWound”) with respect to the matters set forth below:
